Bifidobacterium animalis subsp. lactis BL-99
Gut Health
①Clinical trial:BL-99 could alleviate functional dyspepsia; ②Animal experiment: BL-99 could promote intestinal peristalsis and suppress intestinal inflammation; ③In vitro experiment: The combination of BL-99 and FOS could alleviate constipation.
Bone Health
Animal experiment: BL-99 could mitigate osteoporosis induced by colitisl.
Specification （CFU/g）：400B
Lacticaseibacillus paracasei ET-22
Oral Health
①Clinical trial: This study suggests that both ET-22.L and ET-22.HK can significantly inhibit the production of undesirable odor compounds insubiects with halitosis. ②In vitro experiment: ET-22 (live/heat-killed) could significantly inhibit the growth of oral pathogens.
Gut Health
①In vitro experiment: ET-22 could regulate the balance of intestinal floraintestinal microbiota.②Animal experiment: ET-22 could improve small intestine motility, shorten defecation time, and relieve constipation.
Specification （CFU/g）：400B
Lacticaseibacillus paracasei K56
Weight Management
①Clinical trial:K56 could reduces body fat and visceral fat. ②Animal experimentation: K56 could inhibit the accumulation of body fat and relieve obesity-related symptoms.
Gut Health
Clinical trial: K56 could effectively regulatie the gut microbiotam.
Specification （CFU/g）：400B
Bifidobacterium breve CCFM1025
Regulates Emotions
Clinical trial:CCFM1025 could attenuates depression and associated gastrointestinal disorders.
Improves Sleep
Clinical trial:The sleep quality was improved by significantly reducing the Pittsburgh sleep quality index and the stress markers that affect sleep.
Specification （CFU/g）：150B
Bifidobacterium animalis subsp.lactis CP-9
Weight Management
Clinical trial: Cp-9 could reduce body fat,improves lipid metabolism, and remodels gut ecological dysregulation associated with obesity.
Improvement of Neonatal Jaundice
Clinical trial:lmprovement of neonataljaundicel.
Specification （CFU/g）：400B
1. Efficacy of Bifidobacterium animalis subsp. lactis BL-99 in the treatment of functional dyspepsia: a randomized placebo-controlled clinical. 【https://www.nature.com/articles/s41467-023-44292-x】
2. In vitro Study of Bifidobacterium lactis BL-99 With Fructooligosaccharide Synbiotics Effected on the Intestinal Microbiota.【https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.890316/full】
3. Bifidobacterium lactis BL-99 modulates intestinal inflammation and functions in zebrafish models.
【https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0262942】
4. Function Research of Heat-inactivated Bifidobacterium Lactis BL-99 in Ameliorating Colitis and Regulating Intestinal Microbiota in Mice.【https://kns.cnki.net/kcms2/article/abstract?v=_f4imrocbXl8glO_mtOlBR5lH0jHE90Z-KJIfiPzon4irA7cN0B-hthd0BTOVxp5kH7AY-6Qb5o4ZQ8FjIeFLmPsa0-RWi3naDXlhenWjjBPrtyUeT3O0-SvK88xEzTxqHBRwxlaRaZTZzluTv3wlVXkrNZpIdx8m14MNE98ZHCgD2PLMWgrJmxB0wf3UhZY&uniplatform=NZKPT&language=CHS】
5. Effect of Probiotics on Digestive Enzymatic Activity,Intestinal Mobilityand Mucosal Morphology of Weaned Rodents.
【https://kns.cnki.net/kcms2/article/abstract?v=_f4imrocbXnM3n30bd3fntVZwP3X8QBaIXitAq3B0BgiPlNXR6rub7sWSOv5pjytESQ1DajDcg-0JVwLJJtjNzMIsSFUx0ct1gAZwzl9yP0UfyIHx6iPPPnBNMTy1IpGxTEgIRZ5NiJDt7-v3k86Lvft95pDT-xMEnrvDiWjgqeM_mpDS77xc5qXy_MW1sVy&uniplatform=NZKPT&language=CHS】.
6. Bifidobacterium lactis BL-99 protects mice with osteoporosis caused bycolitis via gut inflammation and gut microbiota regulation.
7. Effects of Bifidobacterium Lactis BL-99 and Lactobacillus Paracasei(Lacticasei Bacillus Paracasei)ET-22 on Regulating lmmune Function in Mice.【https://kns.cnki.net/kcms2/article/abstract?v=_f4imrocbXmY3WlGIWwC9SQTwPkf9qubRacY8WVU9qGpfAJ9c7jFgGeaZCDEYgIvrWytYujgc3uayQe_BCvwtqu-_6u3kVes_xFNS11HYhF7TJlV-1OO7aEWsldRHtKYMI_Sh-HijFnaMIls6RA8VDKtK8RoYIk9TAjq5o3xhhloeyM9-Ol1i4JB4rIcTzRZ&uniplatform=NZKPT&language=CHS】
8. Bifidobacterium animalis subsp. lactis BL-99 ameliorates colitis-related lunginjury in mice by modulating short-chain fatty acid production andinflammatory monocytes/macrophages.
9. Safety Evaluation of Bifidobacterium lactis BL-99 and LacticaseibacillusparacaseiK56 and ET-22 in vitro and in vivo.
10.Strain identification of Bifidobacterium lactis BL-99 isolated from infant intestine.
【https://kns.cnki.net/kcms2/article/abstract?v=_f4imrocbXkx7eT9QWrz5mzsLmkCQW-za0VMMUgZejpb0dfL0hJLp35GoN8tuNxkieD5nRuY6zqN52URLT1poeRUqAMFFqNRAHJhKzk3pfy5tlsgmehVt0MUwgQVNz8jqlrNmdVAro0lXsEcTLhN_s1jMKyWFfoVcp0pc8EEfxrZ8Sy8gaVM88r0jAkpTIzG&uniplatform=NZKPT&language=CHS】
1.Lactobacillus paracasei ET-22 Suppresses Dental Caries by Regulating Microbiota of Dental Plaques and Inhibiting Biofilm Formation.
【https://www.mdpi.com/1420-3049/28/3/1236】
2.Postbiotics Derived from L. paracasei ET-22 Inhibit the Formation of S. mutans Biofilms and Bioactive Substances: An Analysis.
【https://www.mdpi.com/1420-3049/28/3/1236】
3.Lactobacillus paracasei ET-22 and derived postbiotics reduce halitosis and modulate oral microbiome dysregulation -a randomized, double-blind placebo-controlled clinical trial.
4.Preventive effects of Lactobacillus paracasei ET-22 on oral ulcers in golden hamsters and its mechanism.
【https://kns.cnki.net/kcms2/article/abstract?v=UbUZFcLhzII3R-ltU0P798RmeqXI8ixbE39sCg5gAPY-wjRsoqNuRa060omJWTnbaibhUFabUceg24irvWfjmGMQMYkc1F0XDC0ojWoINc9RSdHms9VsPvmhFf8z_667NfYhSB0R25TMkS8vntMz1l5tSI-uBUCiPmov2DXvOe0Fv1skFBcwyamcVYRcYjTS&uniplatform=NZKPT&language=CHS】
5.Effects of Bifidobacterium Lactis BL-99 and Lactobacillus Paracasei (Lacticasei Bacillus Paracasei) ET-22 on regulating immune function in mice China Dairy industry.
【https://kns.cnki.net/kcms2/article/abstract?v=UbUZFcLhzILv9r-KiHdZHZRANOdwE7SF87fzjbVkPh0GoPHk6JNdMeMQ1L4TKiZXMSivAndE6xjuyA357WnM0J5A9_3xpeWPn9lQlU_MUU3KbobAtFKHnySw7I0DPvi6mQISLlKhmfjJLMfaZteZSGIiD0QKBeM83RAjwwhF2oyI7XYU3J7I--9PgcIXyWJu&uniplatform=NZKPT&language=CHS】
6.Effect of probiotics on digestive enzymatic activity, intestinal mobility and mucosal morphology of weaned rodents.
【https://www.spgykj.com/article/doi/10.13386/j.issn1002-0306.2020110084】
7.Safety Evaluation of Bifidobacterium lactis BL-99 and Lacticaseibacillus paracasei K56 and ET-22 in vitro and in vivo.
【https://www.mendeley.com/catalogue/61baaa61-fdc9-3a33-980c-3909d1f78661/】
8.Stability of Lactobacillus paracasei ET-22 after long-term continuous subculturing for 1000 generations.
9.ldentification of Lactobacillus paracasei K56 and ET-22 isolated from human intestine Food and Fermentation Industries.
【https://kns.cnki.net/kcms2/article/abs
1. Effect of different doses of Lacticaseibacillus paracasei K56 on body fat and metabolic parameters in adult individuals with obesity: a pilot study.
【https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/s12986-023-00739-y】
2.Differential Modulation of the Metabolic Effects of Diet-lnduced Obesity by Probiotic Lactobacillus Paracasei K56 and Prebiotic a-Galactooligosaccharides.
3.Effects of Coix seed extract, Lactobacillus paracasei K56, and their combinationon the glycolipid metabolism in obese mice.
【https://ift.onlinelibrary.wiley.com/doi/10.1111/1750-3841.16474】
4.Lacticaseibacillus paracasei K56 Attenuates High-Fat Diet-Induced Obesity by Modulating the Gut Microbiota in Mice.
5.Lacticaseibacillus paracasei K56 inhibits lipid accumulation in adipocytes by promoting lipolysis.
【https://www.sciencedirect.com/science/article/pii/S2213453024002477】
6.Prophylactic treatment of Lacticaseibacillus paracasei K56 ameliorates asthma by regulating short-chain fatty acid production and Treg differentiation.
【https://kns.cnki.net/kcms2/article/abstract?v=Ep7N7zfewyRHTOyHGzlBXOMmpk-R3wGhdmsYCeDpJ8RDltVtI9Owj-rccC2Iwmtw-0gS9bagFHB5cy-XaMLm7HNOBsJYemAiYMJQEdcXLlpkmj1akEuBsVVLt-8T3eKeWLBX9iZgLuf1xQ-eD7uGVRWGVWyqxsBDtgdimgLU15jR-BqehZnC5-XDvJ3wdZQx&uniplatform=NZKPT&language=CHS】
7.Safety Evaluation of Bifidobacterium lactis BL-99 and Lacticaseibacillus paracasei K56 and ET-22 in vitro and in vivo.
【https://www.mendeley.com/catalogue/61baaa61-fdc9-3a33-980c-3909d1f78661/】
1. Bifidobacterium breve CCFM1025 attenuates major depression disorder via regulating gut microbiome and tryptophan metabolism: A randomized clinical trial.
【https://www.sciencedirect.com/science/article/abs/pii/S0889159121006267】
2.Multi-Probiotics ameliorate Major depressive disorder and accompanying gastrointestinal syndromes via serotonergic system regulation.
【https://www.sciencedirect.com/science/article/pii/S2090123222001151】
3.Unraveling the Microbial Mechanisms Underlying the Psychobiotic Potential of a Bifidobacterium breve Strain.
【https://onlinelibrary.wiley.com/doi/10.1002/mnfr.202000704】
4.Towards a psychobiotic therapy for depression: Bifidobacterium breve CCFM1025 reverses chronic stress-induced depressive symptoms and gut microbial abnormalities in mice.
【https://www.sciencedirect.com/science/article/pii/S2352289520300060】
5.Bifidobacterium breve CCFM1025 lmproves Sleep Quality via Regulating the Activity of the HPA Axis: A Randomized Clinical Trial.
【https://www.mdpi.com/2072-6643/15/21/4700】
6.Probiotics Administration Alleviates Cognitive lmpairment and Circadian Rhythm Disturbance Induced by Sleep Deprivation.
【https://www.sciencedirect.com/science/article/pii/S2213453024001691】
7.Administration of Bifidobacterium breve lmproves the Brain Function of AB1-42-Treated Mice via the Modulation of the Gut Microbiome.
【https://www.mdpi.com/2072-6643/13/5/1602】
SCI-1 (IF:3.9)：Heat-killed lactic acid bacteria enhance immunomodulatory potential by skewing the immune response toward to Th1 polarization.
【https://pubmed.ncbi.nlm.nih.gov/22417436/】
SCI-2 (IF:3.1)：Bacteriostatic activities of lactic acid bacteria against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli.
【https://onlinelibrary.wiley.com/doi/10.1111/bcpt.13350】
SCI-3 (IF:3.1)：Bacteriostatic abilities of viable and heat-killed lactic acid bacteria against group B Streptococcus.
SCI-4 (IF:3.1)：Assessment of bacteriostatic activities of viable and non-viable lactic acid bacteria against methicllin-resistant Staphylococcus aureus.
SCI-5 (IF:2.4)：Antibacterial activity of viable and heat-killed probiotic strains against oral pathogens.
【https://pubmed.ncbi.nlm.nih.gov/31955445/】
SCI-6 (IF:3.7)：Multi-strain probiotic supplement attenuates streptozotocin-induced type-2 diabetes by reducing inflammation and β-cell death in rats.
【https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0251646】
SCI-7 (IF:2.6)：Viable and Heat‑Killed Probiotic Strains Improve Oral Immunity by Elevating the IgA Concentration in the Oral Mucosa.
【https://pubmed.ncbi.nlm.nih.gov/34345965/】
SCI-8 (IF:5.9)：A Combined Supplement of Probiotic Strains AP-32, bv-77, and CP-9 Increased Akkermansia mucinphila and Reduced Non-Esterified Fatty Acids and Energy Metabolism in HFD-Induced Obese Rats.
【https://pubmed.ncbi.nlm.nih.gov/35276886/】
SCI-9 (IF:5.2)：Adjuvant probiotics of lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and bifidobacterium animalis subsp. lactis CP-9 attenuate glycemic levels and in flammatory cytokines in patients with type 1 diabetes mellitus.
【https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.754401/full】
SCI-10 (IF:3.9)：Safety and the probiotic potential of Bifidobacterium animalis CP-9.
【https://pubmed.ncbi.nlm.nih.gov/35347713/】
SCI-11 (IF:5.0)：A multi-strain probiotic blend reshaped obesity-related gut dysbiosis and improved lipid metabolism in obese children.
SCI-12 (IF:1.6)：Adjuvant probiotic Bifidobacterium animalis subsp. lactis CP-9 improve phototherapeutic treatment outcomes in neonatal jaundice among full-term newborns: A randomized double-blind clinical study.
